Polyguard Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 26 Year, 1 Day
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.15 M
- Revenue Growth 14.23%
- Profit Growth -80.59%
- Ebitda -0.01%
- Net Worth -1.08%
- Total Assets -3.59%
About Polyguard Drugs
Polyguard Drugs Private Limited (PDPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 February 1999 and has a history of 26 years. Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.15 M.
Anjali Jaiswal, Roy Jaiswal, and Pratyaksh Jaiswal serve as directors at the Company.
Company Details
-
Location
Lucknow, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U85193UP1999PTC024190
-
Company No.
024190
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 Feb 1999
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
What products or services does Polyguard Drugs Private Limited offer?
Polyguard Drugs Private Limited offers a wide range of products and services, including Pharmaceutical Syrup, Dry Syrups, Antibacterial Drugs, Antibiotic Medicine, Pain Balm & Ointments, Ayurvedic Pain Balm, Antacid Drugs, Allopathic Liver Tonic, Pharmaceutical Capsules, Cough Syrup.
Who are the key members and board of directors at Polyguard Drugs?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anjali Jaiswal
|
Director | 11-Feb-1999 | Current |
|
Roy Jaiswal
|
Director | 11-Feb-1999 | Current |
|
Pratyaksh Jaiswal
|
Director | 02-Dec-2019 | Current |
Financial Performance of Polyguard Drugs.
Polyguard Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 14.23% increase. The company also saw a substantial fall in profitability, with a 80.59% decrease in profit. The company's net worth dipped by a decrease of 1.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Polyguard Drugs?
In 2022, Polyguard Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.15 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.07 Cr
- Bank Of India : 0.03 Cr
- Centurion Bank Ltd. : 0.01 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Jun 2022 | Hdfc Bank Limited | ₹0.71 M | Open |
| 31 Mar 2008 | Bank Of India | ₹0.30 M | Open |
| 28 May 2005 | Centurion Bank Ltd. | ₹0.14 M | Open |
How Many Employees Work at Polyguard Drugs?
Unlock and access historical data on people associated with Polyguard Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Polyguard Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Polyguard Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.